JHS Svendgaard narrows net loss to ₹192.24 lakh in FY26
JHS Svendgaard Laboratories Limited narrowed its net loss to ₹192.24 lakh for FY26 from ₹1,974.43 lakh in the previous year, while revenue from operations increased to ₹10,169.47 lakh. The board approved the audited financial results on May 26, 2026, and the statutory auditors issued an unmodified opinion.

*this image is generated using AI for illustrative purposes only.
JHS Svendgaard Laboratories Limited narrowed its net loss to ₹192.24 lakh for the financial year ended March 31, 2026, from a loss of ₹1,974.43 lakh in the previous year. Revenue from operations for the year rose to ₹10,169.47 lakh, compared to ₹9,199.73 lakh in FY25, while total income stood at ₹10,514.34 lakh. The company's board of directors approved the audited standalone and consolidated financial results at a meeting held on May 26, 2026. The statutory auditors, M/s V.K. Khosla & Co., issued an unmodified opinion on the financial results.
Financial Performance
The company reported a basic and diluted earnings per share (EPS) of (₹0.22) for FY26, an improvement from (₹2.37) in the prior year. For the quarter ended March 31, 2026, the net loss was ₹356.56 lakh, with revenue from operations at ₹3,269.57 lakh. The board also took note of the Auditor’s Report issued by the statutory auditors. The paid-up equity share capital of the company stands at ₹8,740.58 lakh, comprising 8,74,05,767 equity shares of ₹10 each, following the conversion of warrants.
| Metric | FY26 (₹ in lakh) | FY25 (₹ in lakh) |
|---|---|---|
| Revenue from Operations | 10,169.47 | 9,199.73 |
| Total Income | 10,514.34 | 9,487.44 |
| Net Profit/(Loss) | (192.24) | (1,974.43) |
| Basic EPS (₹) | (0.22) | (2.37) |
Operational and Capital Details
The company utilized funds raised through preferential allotment for projects in Jammu and Kashmir, general corporate purposes, and capital expenditure. Capital advances amounting to ₹3,252.75 lakh for facilities in Himachal Pradesh and ₹1,328.30 lakh for projects in Jammu & Kashmir were considered recoverable by the management. The auditors noted material weaknesses in internal financial controls over financial reporting, specifically regarding the reconciliation of trade receivables and payables, and the identification of non-moving inventory. The meeting was conducted pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for JHS Svendgaard Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.63% | -9.74% | -11.05% | -22.62% | -39.35% | -65.20% |
What specific measures will management implement to address the material weaknesses identified in internal financial controls?
How will the capital advances for the Himachal Pradesh and Jammu & Kashmir facilities impact production capacity in the coming fiscal year?
Is the company on track to achieve a net profit in FY27 given the significant reduction in losses year-over-year?


































